By Ethan Faverino |
A new national poll conducted by Pulse Decision Science reveals that pharmaceutical reform represents a powerful and politically advantageous issue for Republican candidates heading into this election cycle.
The data shows the issue effectively consolidates support within the GOP base during primaries while delivering meaningful gains among independent and battleground voters in general elections.
The poll highlights near-universal frustration with the high costs of prescription drugs, creating a rare opportunity for Republicans to claim ownership of an issue that resonates deeply across demographic and partisan lines.
According to the survey, 84% of voters report using prescription medication, underscoring how broadly the issue affects American households. Cost pressures are forcing significant behavioral changes, with 55% of respondents admitting they have skipped doses, turned to over-the-counter alternatives, or ignored doctor recommendations due to high prices.
These coping behaviors are particularly common among younger women, lower-education voters, and independents/moderates.
Voters across the political spectrum overwhelmingly attribute rising drug prices to pharmaceutical industry practices rather than investments in innovation. Major factors cited include:
- Increasing profits: 81%
- Rising executive compensation: 76%
- Unethical business practices: 70%
By contrast, only 52% of voters view research and development costs as a major driver of prices—the weakest factor identified by a wide margin.
This perception creates fertile ground for messaging focused on corporate greed, price gouging, and unfair practices, which the poll indicates resonates strongly even with the Republican base.
When voters are presented with a candidate who supports specific, targeted pharmaceutical reforms—including Most Favorable Nation (MFN) pricing, patent reform, and measures to increase competition—that candidate sees a net +5-point gain in overall support.
Notable gains were recorded among key subgroups:
- Hispanics: +10 points
- High-propensity general election voters (3 of 4 voting history): +9 points
- Women 55 and older: +7 points
- Voters in lean Democratic Congressional districts: +7 points
- High school education or less: +7 points
- Republicans: +6 points
- Conservatives: +6 points
- Bachelor’s degree holders: +6 points
These shifts demonstrate that pharmaceutical reform serves both a base-unifying issue and a tool for expanding appeal in competitive general election environments.
The poll further shows that framing pharmaceutical reform through an “America First” lens is especially powerful in Republican primaries. Fully 89% of GOP primary voters indicated they are more likely to support a candidate who prioritizes codifying President Trump’s Most Favorable Nation Executive Order.
When paired with messaging that emphasizes America-First pricing, the issue delivers strong consolidation within the Republican coalition. Key subgroup gains in the primary context include:
- Males 18-34: +13 points
- Voters in lean Republican Congressional districts: +11 points
- Mid-turnout voters (2 of 4 voting history): +10 points
- Self-described “Not So Strong” Republicans: +10 points
The findings arrive as the Trump administration continues to focus on delivering tangible results on pharmaceutical pricing. On April 23, 2026, President Trump announced the 17th agreement with a major pharmaceutical manufacturer—this time with Regeneron—bringing MFN-style pricing to American patients.
The deal provides every State Medicaid program access to MFN prices on Regeneron products, delivering hundreds of millions in savings. It covers 86% of the branded drug market across 17 leading manufacturers and includes commitments to end foreign freeloading on American innovation.
Key provisions include significant price reductions, such as lowering the price of Regeneron’s cholesterol medication, Praluent, from $537 to $225 when purchased through TrumpRx.
Additionally, Regeneron’s new gene therapy for a rare form of genetic deafness, Otarmeni, will be provided at no cost to American families. The company also committed to a $27 billion investment in U.S. research, development, and manufacturing by 2029, contributing to a total of $448 billion in pharmaceutical investments secured under President Trump in just 15 months.
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
